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Chronic hepatitis B virus (HBV) infection remains a serious disease, mainly due to its 
severe pathological consequences, which are difficult to cure using current therapies. 
When the immune system responds to hepatocytes experiencing rapid HBV replica-
tion, effector cells (such as HBV-specific CD8+ T cells, NK cells, NKT cells, and other 
subtypes of immune cells) infiltrate the liver and cause hepatitis. However, the precise 
recruitment of these cells remains unclear. In the present study, we found that the 
cytoplasm-translocated Ku70/80 complex in liver-derived cells sensed cytosolic HBV 
DNA and promoted hepatitis-associated chemokine secretion. Upon sensing HBV DNA, 
DNA-dependent protein kinase catalytic subunit and PARP1 were assembled. Then, 
IRF1 was activated and translocated into the nucleus, which upregulated CCL3 and 
CCL5 expression. Because CCR5, a major chemokine receptor for CCL3 and CCL5, is 
known to be critical in hepatitis B, Ku70/80 sensing of HBV DNA likely plays a critical role 
in immune cell recruitment in response to HBV infection.
Keywords: hBV, Dna sensor, chemokine, innate immunity, irF1
inTrODUcTiOn
According to data from the World Health Organization, hepatitis B virus (HBV) infection is 
an ongoing major health concern worldwide, with an estimated 240 million people chronically 
infected. Moreover, HBV-associated complications, including cirrhosis and liver cancer, kill more 
than 780,000 people worldwide annually (1). Unfortunately, the major HBV therapies currently 
available, such as interferon and/or nucleotide analog treatments, are unsatisfactory in terms of 
virus eradication (2). Although much knowledge regarding this enigmatic disease remains unclear, 
researchers have identified some common immune responses in hepatitis B. For example, various 
immune cell types play a role in the development of acute and chronic hepatitis, including NK, 
CD4+ T, and CD8+ T cells (3). These cells accumulate at the site of infection and contribute to the 
process of hepatitis, resulting in hepatocyte damage and an increase in serum alanine aminotrans-
ferase (ALT). However, the way in which the recruitment of immune cells is initiated requires 
further elucidation. Many studies have revealed the crucial roles of cytokines during viral hepatitis 
progression, and these include immune cell activation and suppression (4–6), viral clearance (7, 8), 
TaBle 1 | characteristics of hBV patients.
characteristics Pre-treatment Treatment for 48 weeks
HBsAg (SD), IU/ml 29,945 (43,519) 6107 (8084)
HBeAg (SD), COI 676 (434) 212 (368)
Cases 20
Male 13
Mean age (SD) 30.7 (7.5)
HBV genotype B(9), C(11)
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and effector cell recruitment (9–11). Determining how the first 
round of cytokine secretion occurs, which leads to the resulting 
cascade of immune reactions, is thus essential to understand the 
mechanisms underlying viral hepatitis.
The innate immune system serves as the vanguard in host 
defense, before the adaptive immune system responds. Pattern-
recognition receptors (PRRs) recognize pathogen-associated 
molecular patterns (PAMPs) at the front line of the interaction 
between host and pathogen and subsequently engage various 
pathways that lead to host-protective mechanisms (12). As all 
microbes contain DNA and/or RNA, nucleic acids constitute an 
important type of PAMP, especially in viral infection. Recently, 
numerous studies on cytosolic nuclear acid-sensing pathways 
have identified the key roles of cytosolic nuclear acid sensors in 
protecting the host against invading pathogens (13). Regarding 
HBV, a DNA virus with a special life cycle that involves reverse-
transcribed genomic DNA, both viral RNA and DNA, are present 
in the host cell cytoplasm (14–16). RIG-I has been shown to 
be responsible for HBV pre-genomic RNA (pgRNA) sensing 
and antiviral activity in HBV-expressing cells (17). In human 
immunodeficiency virus (HIV) infection and other retrovirus 
infections, cyclic GMP-AMP synthase (cGAS) acts as an impor-
tant sensor of cDNA (18–20). The DNA sensor IFI16 has also 
been shown to be involved in the response to viral infection (21, 
22). Considering the similar reverse transcription replication 
strategy of HBV and retroviruses, it seems possible that similar 
DNA-sensing pathways exist in HBV infection. For instance, 
cGAS has been reported to be required for the innate immune 
response against HBV (23). However, much is unknown about 
HBV DNA sensing.
In this study, we observed that chemokines, especially CCL5, 
are expressed at very high levels in patients with HBV-associated 
disease, by using data mining of the Gene Expression Omnibus 
(GEO). Serum test results of HBV patients and Ad-HBV infection 
of mice also confirmed this observation. CCL5 and CCL3 are well 
characterized as inflammation-associated chemokines (24–26), 
and their main receptor, CCR5, is also essential in hepatitis B 
progression (27). We found that the Ku70/80 complex senses 
HBV DNA in the cytoplasm and upregulates CCL3 and CCL5 
expression in an HBV DNA transfection model. The Ku70/80 
complex is well known to be a DNA damage repair factor that 
monitors DNA breaks and non-homologous end joining (NHEJ) 
in the nucleus (28). Although Ku protein translocation to the 
cytoplasm has been reported about a decade ago (29, 30), it was 
not until recently that Ku’s DNA sensor capability was identified 
(31, 32). Zhang et al. revealed that Ku70 senses DNA in different 
forms and promotes type III interferon expression in an IRF1/
IRF7-dependent manner. In addition, data reported by Ferguson 
et al. showed that Ku proteins sense viral DNA together with the 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) 
and that signal transduction involves TBK1–IRF3. Moreover, 
when the DNA-binding capability of Ku70/80 complex is blocked 
by vaccinia virus component C16, cytokines, such as IL-6, 
CXCL10, induced by DNA stimulation is downregulated (33). 
The data reported in this study identify a different mechanism 
by which the Ku70/80 complex coordinates with DNA-PKcs and 
PARP1 to activate an IRF1-dependent pathway and upregulate 
CCL3 and CCL5 chemokine expression upon sensing HBV DNA 
in the cytoplasm. In Ad-HBV-infected mice, CCL3 and CCL5 
contributed to the recruitment of effector immune cells to the 
liver and promoted hepatitis. Moreover, knockdown of Ku70 
expression significantly affected CCL3 and CCL5 secretion. 
Considering the critical role of CCR5 in hepatitis B (27), this type 
of DNA-sensing-dependent chemokine upregulation mechanism 
may explain how immune cells are recruited in response to HBV 
infection.
MaTerials anD MeThODs
geO Dataset analysis
Gene expression profile data (GSE38941 and GSE65359) were 
downloaded from GEO: https://www.ncbi.nlm.nih.gov/geo (34). 
Student’s t-tests, hierarchical clustering, and heat map analysis 
were performed using MultiExperiment Viewer (MeV) (35). 
Gene set enrichment analysis (GSEA) was performed using the 
GSEA software (36).
hBV-infected Patients
Twenty patients with chronic hepatitis B were selected randomly 
from the cohort studied in our lab previously (37). The patients 
received continuous antiviral treatment of 1.5 μg/kg Peg-IFNα-2b 
(PegIntron, Schering-Plough, Kenilworth, NJ, USA) weekly or 
Peg-IFNα-2b weekly combined with 10  mg adefovir dipivoxil 
(ADV, Hepsera, Gilead Sciences, Foster City, CA, USA) daily for 
48 weeks. Patient sera collected at 0 and 48 weeks were tested for 
CCL5 concentration by BD Cytometric Bead Array.
All serum samples of HBV patients were collected at the 
Department of Infectious Diseases, the First Affiliated Hospital 
of Anhui Medical University from June 2012 to July 2014. Written 
informed consent was obtained from all patients donating blood 
samples. The study was approved by the ethics committee of the 
First Affiliated Hospital of Anhui Medical University (Grant 
No. K2010003) and was carried out in accordance with the 
approved guidelines. This clinical research was also enrolled in 
the Chinese Clinical Trial Registry (Clinical trial registration 
number: ChiCTR-TRC-12002226). The characteristics of the 
HBV patients are listed in Table 1.
cell culture
The cell lines SK-Hep-1 and Huh 7 were provided by the Cell Bank 
of the Chinese Academy of Sciences. The cell lines HepG2, HepG 
2.2.15, and 293A were maintained in our laboratory. The cells 
were cultured in DMEM containing 10% FBS (Sigma or Gibco) 
and antibiotics (100  U/ml penicillin, 80  μg/ml streptomycin). 
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Human sinusoidal endothelium cells (HSECs) were purchased 
from Sciencell. The HSECs were cultured with Endothelial Cell 
Medium (Sciencell) at 37°C with 5% CO2, and the culture medium 
was renewed every other day.
Plasmid construction
The pAAV-HBV1.2 plasmid was provided by Pei-Jer Chen 
(National Taiwan University, Taipei) and maintained in our labo-
ratory. The pAAV plasmid was subcloned from pAAV-HBV1.2.
The HBV subtype adw sequence was subcloned from the 
rAAV-HBV1.3 virus (FivePlus Molecular Medicine Institute, 
Beijing, China). The pAAV-HBV1.3 plasmid was constructed 
by ligating 1.3 copies of the HBV sequence (subtype “adw,” 
NsiI + EcoRI-cleaved fragment, and EcoRI + BglII-cleaved frag-
ment) into the pAAV plasmid. The pAAV-HBV1.3 plasmid was 
digested using NsiI, and the HBV sequence fragment was cleaved 
off and then ligated into the NsiI-linearized pAAV-HBV1.3 plas-
mid to construct the pAAV-HBV2.3 plasmid.
CCL3 promoter (2  kbp upstream CCL3) was cloned and 
inserted to replace the CMV promoter of pEGFP plasmid. Then, 
luciferase reporter sequence was cloned downstream the CCL3 
promoter to construct pCCL3p-luc-eGFP plasmid.
cell Transfection
Plasmid transfection of SK-Hep-1, Huh 7, and HepG 2 cells 
was performed using Lipofectamine 2000 or Lipofectamine 
3000 (Invitrogen). HSECs were transfected with FuGENE HD 
(Promega). siRNAs were synthesized by GenPharma, Shanghai, 
China, and then transfected into cells with RNAiMAX 
(Invitrogen). Cells were plated 24  h before transfection. All of 
the transfection experiments were performed according to 
the manufacturer’s instructions. Briefly, 1  μg/ml plasmid was 
transfected using 4 μl Lipofectamine 2000/3000 or 2 μl FuGENE 
HD. The 20 pmol siRNA was transfected with 4 μl RNAiMAX 
in 24-well plate. Fresh culture medium with 10% FBS was added 
24 h post-transfection.
luciferase reporter assay
SK-Hep-1 cells were transfected with pCCL3p-luc-eGFP plas-
mid and selected with G418 (Gibco) for stable expression. Then, 
the cells were challenged with different stimulants. Forty-eight 
hours later, 150 μg/ml of firefly luciferin was added to the cell 
culture supernatant and bioluminescence was determined 
immediately.
Determination of chemokine levels by 
enzyme-linked immunosorbent assay
Cell culture supernatant was collected and centrifuged at 16,000 g 
for 10  min to remove cell fragments, and serum samples were 
prepared by spinning coagulated blood and collecting the super-
natant. Tissue samples were grinded with cell lysis buffer on ice 
centrifuged at 16,000  g for 10  min, and then the supernatant 
was collected. CCL3 and CCL5 enzyme-linked immunosorbent 
assay (ELISA) kits were purchased from R&D. Experiments were 
carried out according to the protocols of the manufacturer’s 
instructions.
hBV Dna labeling, Pulldown, and Mass 
spectrometry
Biotin-labeled HBV DNA was amplified by PCR with the 
5′- biotin sense primer and anti-sense primer from the pAAV-
HBV2.3 plasmid, excised from the agarose gel, and then trans-
fected into SK-Hep-1 cells for 6 h. Then, the cells were lysed with 
NP-40 lysis buffer (150 mM NaCl, 50 mM Tris–HCl, pH = 7.4, 
1  mM freshly added PMSF). The DNA-binding proteins were 
pulled down with a μMACS Streptavidin kit (Miltenyi Biotec). 
Mass spectrometry results were obtained by APTbiotech, 
Shanghai, China. Briefly, protein samples were digested with 
trypsin for 20 h. Then, protein peptides were identified by liq-
uid chromatography (Zorbax 300SB-C18; Agilent) and tandem 
mass spectrometry (Thermo Finnigan). The mass spectral data 
were searched against UniProt human proteomic database using 
the Mascot 2.2 software.
Mouse Protocols
C57BL/6 mice were purchased from Vitalriver, Beijing, China. 
All mice were kept in a specific pathogen-free (SPF) microen-
vironment, receiving care in compliance with the guidelines set 
forth in the Guide for the Care and Use of Laboratory Animals. 
All experiments were approved by the Ethical Review Board of 
the School of Life Science, University of Science and Technology 
of China. Mice aged between 6 and 8 weeks were used for these 
experiments. For virus infection, the plasmid of recombinant 
adenovirus that transfers a 1.3-fold overlength HBV genome 
(Ad-HBV) was provided by Prof. Ulrike Protzer (Technischen 
Universität München). Ad-null virus was purchased from the 
FivePlus Molecular Medicine Institute. The virus was packaged 
and amplified in 293A cells, and the titer was determined by 
plaque formation. A total of 1 × 109 pfu/200 μl virus was injected 
intravenously (i.v.) into each mouse. Six days later, the mice were 
sacrificed.
hepatic Mononuclear cell isolation and 
Flow cytometry
Livers were ground to pass through a 200-gauge stainless steel 
mesh. The precipitate was re-suspended in 40% Percoll (Sigma) 
and centrifuged at 2400  rpm for 10  min at room temperature. 
Then, the precipitate was collected and re-suspended in RBC 
Lysis Buffer (BioLegend), incubated at room temperature for 
10–15  min, and then washed twice in PBS. Splenocytes were 
obtained in the same manner, except for Percoll re-suspension. 
Flow cytometry was performed, as previously described (38).
BD cytometric Bead array
Samples were diluted according to the manufacturer’s instruc-
tions if necessary. Then, incubated with the mixed beads at 4°C 
for 30 min, washed the beads with PBS twice, and applied them 
on flow cytometry.
serum Transaminase assay
Serum ALT activity was measured using a commercially available 
kit (Rong Sheng, Shanghai, China).
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immunofluorescence staining
Cells or frozen tissue sections were fixed in 4% paraformaldehyde 
(PFA) for 15–20  min, followed by permeabilization with 1% 
Triton X-100 for 15–20 min, and blocking with 5% donkey serum 
for 1 h at room temperature. Then, the sections were incubated 
with the primary antibodies at 4°C overnight. Secondary anti-
bodies were incubated with the sections at 37°C for 3 h. The nuclei 
were stained with DAPI (1 ng/ml) for 3 min at room temperature. 
Confocal images were acquired on a Zeiss LS710 microscope, and 
GSD super-resolution images were acquired using the Leica 3D 
GSD system.
mrna isolation, reverse Transcription 
Pcr, and real-time Pcr
Cell or tissue mRNA was isolated with TRIzol and reverse tran-
scribed into cDNA with M-MLV (Invitrogen). Relative quantita-
tive real-time PCR analysis was performed on Roche LightCycler 
96 using the SYBR Premix Ex Taq II (Takara). These data were 
analyzed using ΔΔCt method.
cytosolic and nuclear Protein extraction
Cells were lysed on ice for 30  min with cytoplasm extraction 
buffer (10 mM HEPES, 40nM KCl, 2mM MgCl2, 10% glycerol, 
and 1mM PMSF). The cells were lysed on ice for 30  min with 
cytoplasm extraction buffer (10 mM HEPES, 40 nM KCl, 2 mM 
MgCl2, 10% glycerol, and 1 mM PMSF). The cells were centrifuged 
at 2000 rpm for 5 min at 4°C, and the supernatant was collected. 
The supernatant was then centrifuged at 14,000 rpm for 15 min at 
4°C. The supernatant was the cytosolic protein solution, and the 
pellet was used as the nuclear protein sample.
co-immunoprecipitation
Cells were lysed with 500 μl NP-40 lysis buffer, and then cen-
trifuged at 14,000 rpm for 15 min at 4°C. The supernatant was 
collected, added in 30  μl protein G-Agarose beads (Sangon, 
Shanghai) together with 1–10  μg isotype IgG antibody, and 
incubated at 4°C for 1 h with gentle agitation. Then, centrifuged 
and the beads were discarded, the supernatant added in 30 μl 
protein G-Agarose beads and 1–10 μg intended antibody. It was 
incubated at 4°C overnight with gentle agitation. Centrifuged to 
collect down the beads and washed three times in lysis buffer.
Western Blot
Protein samples were applied to SDS-PAGE, and then transferred 
to PVDF membrane (0.45 μm, Millipore). It was incubated with 
the primary antibody at 4°C overnight or 3 h at room temperature. 
The membrane was washed in TBST for three times, 5 min each, 
followed by incubation of HRP-conjugated secondary antibody at 
room temperature for 1 h. The membrane was washed four times 
in TBST, and then developed it with SuperSignal West Femto 
Maximum Sensitivity Substrate (Thermo Fisher).
antibodies
Ku70, Ku80, PARP1, IRF1, cGAS, STING primary antibodies, 
anti-HBsAg, and anti-HBcAg were purchased from Abcam. IRF3, 
IRF7, RNA pol III, CCL3, and CCL5 antibodies were purchased 
from Santa Cruz. Secondary antibodies labeled with Alexa Flour 
were all purchased from Invitrogen. Mouse antibodies were all 
purchased from BD Bioscience, except for CD8 primary antibody 
from eBioscience. Refer to Table S1 in Supplementary Material 
for detailed information.
Pcr Primers and sirna sequences
For detailed information on PCR primers and siRNA sequences, 
see Table S1 in Supplementary Material.
statistical analyses
We used Student’s t-tests to compare the mean values between 
groups. Bars represent the SD of each group (*p  <  0.033, 
**p < 0.002, ***p < 0.0002, and ****p < 0.0001).
resUlTs
chemokines ccl3 and ccl5 are involved 
in hepatitis B
To identify HBV infection-related factors, we searched HBV-
associated gene expression profiles in GEO. In dataset GSE38941, 
which consisted of liver specimens from patients with HBV-
associated acute liver failure (ALF) and healthy donors (39), 
we noticed that most of the chemokines were significantly 
upregulated in the livers of patients compared with healthy 
donors (Figure 1A). A GSEA plot of the chemokine activity gene 
set also showed a strong enrichment of chemokines in the livers 
of patients (Figure 1B). In particular, CCL5 had a top-ranked 
p-value among genes that were significantly different between 
patients and donors (Figure 1C). The absolute expression of CCL5 
in HBV-associated ALF patients was also much higher than that 
in healthy donors (Figure  1D). In another dataset, GSE65359 
(40), which consisted of which consisted of liver specimens from 
HBV-infected patients in the immune tolerance, immune clear-
ance, and chronic phases, some chemokines were also highly 
expressed in patients in the immune clearance phase (Figure 
S1A in Supplementary Material). Of these chemokines, CCL5 
showed a very significant difference and high expression levels 
in immune clearance group (Figures S1B,C in Supplementary 
Material). Considering the symptoms of hepatitis in patients 
with HBV-associated ALF and in patients of immune clearance 
phase, these data suggest that CCL5 is important in hepatitis B. 
Next, we tested the serum of HBV patients receiving continuous 
antiviral treatment (Table 1). As expected, when the hepatitis-
related symptoms of ALT level and HBV DNA copy number 
decreased, the CCL5 concentration in the patient serum also 
decreased (Figure 1E).
We used an Ad-HBV infection model of acute viral hepatitis 
in C57BL/6 mice (41) to determine whether inflammation-
associated chemokines were present at higher levels during 
HBV-mediated hepatitis. As previously reported, mice infected 
with Ad-HBV showed a high level of serum ALT, which indi-
cated severe liver damage. Meanwhile, the serum CCL5 level was 
significantly increased in Ad-HBV infection group (Figure 2A). 
When we examined the expression of CCL3 and CCL5 in the 
liver, both protein secretion and mRNA expression increased 
FigUre 1 | chemokines, especially ccl5, are highly expressed in the livers of patients with hBV-associated disease. (a) Heat map of chemokine 
expression in GSE38941. These data were normalized with MeV. (B) GSEA of the chemokine activity gene set in GSE38941. (c) Genes with top-ranking p-values 
from Student’s t-tests comparing the expression profiles of liver samples from HBV-associated ALF patients with those of healthy donors. These data were 
derived from GSE38941. (D) Scatter plot of genes with p-values less than 0.01 in (a). Three CCL5 probes are indicated. (e) The levels of CCL5, ALT, and HBV 
DNA were measured in the serum of patients with hepatitis B. 0 W, serum samples before antiviral treatment; 48 W, serum samples after 48 weeks of antiviral 
treatment (n = 20).
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dramatically (Figures 2B,C). CCL3 is another ligand for CCR5, 
and because CCL3 and CCL5 possess strong chemotactic activ-
ity for CCR5+ circulating cells, a large number of immune cells 
infiltrated the liver in response to the increased expression of 
these chemokines (Figure  2D). In comparison, mononuclear 
cells in the spleen exhibited no changes. Analysis of the subtypes 
of infiltrating lymphocytes revealed a major population of 
CD8+ T cells (Figure 2E), which tended to be HBV specific and 
constituted the main cause of hepatitis, according to a previous 
publication (41). In addition, the accumulation of NK and CD4+ 
T cells was also substantial, although not as large as that of CD8+ 
T cells (Figure 2F).
We next investigated chemokine and immune cell localization 
using frozen liver sections. As expected, the livers of Ad-HBV-
infected mice showed robust lymphocyte infiltration, and the 
hepatocytes with HBV replication secreted a large amount of 
CCL3 (Figure 2G). These data reveal that CCL3 and CCL5 are 
hepatitis-associated immune factors.
FigUre 2 | ad-hBV infection induces the secretion of inflammation-associated chemokines in the liver. (a–g) C57BL/6 mice were injected i.v. with 
1 × 109 pfu Ad-HBV/200 μl PBS (Ad-HBV group) or 1 × 109 pfu Ad-null/200 μl PBS (Ad-null group). About 200 μl of PBS was injected as a normal control (PBS 
group). Six mice were included in each group. Six days post-injection, the mice were sacrificed for the analysis. (a) Serum ALT and CCL5 levels in the mice. 
(B) CCL3 and CCL5 levels in the mouse livers. (c) CCL3 and CCL5 mRNA expression levels in the mice. (D–F) Mouse livers were harvested for weighing and 
mononuclear cell isolation. The numbers of total mononuclear cells in the livers and spleens were counted (D). Then, the lymphocyte subtypes were analyzed by 
flow cytometry (e). The number of cells of each lymphocyte subtype was calculated (F). Frozen sections of mouse livers were stained for HBsAg and CCL3 using 
immunofluorescence. Scale bars: 30 μm (g).
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hBV Dna Transfection Upregulates 
ccl3 and ccl5 expression in  
liver-Derived cells
Chemokine expression can be regulated in various ways in dif-
ferent types of cells. However, whether HBV directly stimulates 
liver cells to express CCL3 and CCL5 remains to be determined. 
To imitate HBV genomic DNA presentation in the cytoplasm, we 
transfected the pAAV-HBV1.2 plasmid into liver-derived cells, 
i.e., SK-Hep-1, HepG 2, Huh 7, and primary HSECs. Forty-eight 
hours later, we evaluated the changes in mRNA expression encod-
ing several inflammation-associated cytokines (Figure 3A). The 
PCR bands revealed that the chemokines CCL3 and CCL5 were 
strongly increased in HSEC and SK-Hep-1 cells, despite other 
weak changes. Further real-time qPCR showed that, although 
some other cytokines such as IL-6 were significantly upregu-
lated, the fold changes in CCL3 and CCL5 were much higher 
(Figures  3B,D). Meanwhile, CCL3 and CCL5 secretion into 
HBV plasmid-transfected SK-Hep-1 cell supernatants increased 
robustly (Figure  3E), confirming the results of mRNA level. 
Notably, IFN-β, a cytokine that is widely involved in cytosolic 
innate immune responses, showed an increased mRNA level after 
HBV plasmid transfection (Figures 3A,D). However, IFN-β was 
barely detectable in the cell culture supernatant (data not shown), 
which is similar to HBV infection in vivo. This transfection model 
showed that HBV DNA stimulation directly upregulates CCL3 
and CCL5 expression in liver-derived cells.
We next constructed two additional types of HBV plasmid 
containing 1.3 or 2.3 copies of HBV genomic DNA (Figure 
S2A in Supplementary Material). In this transfection model, 
the induction of CCL3 and CCL5 did not depend on the HBV 
DNA insertion length of the plasmids; all three plasmids effi-
ciently stimulated SK-Hep-1 cells (Figure S2B in Supplementary 
Material). However, chemokine upregulation depended on the 
stimulant dosage (Figure S3A in Supplementary Material) and 
stimulation duration (Figure S3B in Supplementary Material), 
and we chose 1 μg/ml and 48 h as optimal conditions for subse-
quent experiments.
The cytoplasm-Translocated  
Ku70/80 complex recognizes 
Transfected hBV Dna
Although CCL3 and CCL5 are hepatitis associated, precisely 
how their expression is regulated remains unclear. Upon observ-
ing that cells respond quite rapidly to HBV DNA, within 24 h 
(Figure S3B in Supplementary Material), and considering that 
an autocrine feedback mechanism might not be sufficient, we 
FigUre 3 | ccl3 and ccl5 expression increases in liver-derived cells upon hBV plasmid transfection. (a–e) The pAAV-HBV1.2 or pAAV plasmid 
(1 μg/ml) was transfected into liver-derived cells (0.2 μg/ml for HSECs). Transfection reagent was only applied as a control. RNA isolation and reverse transcription 
proceeded 48 h post-transfection. (a) PCR detection of inflammation-associated chemokine and cytokine mRNAs. (B–D) Real-time qPCR determination of 
chemokine and cytokine mRNA expression (n = 3). (e) ELISA determination of the secreted CCL3 and CCL5 levels in the cell culture supernatant (n = 3).
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hypothesized that this response was due to direct nucleic acid 
sensing. As the backbone vector pAAV contained no open read-
ing frames (ORFs) and did not stimulate the cells in comparison 
to the HBV plasmids (Figure  3; Figure S2 in Supplementary 
Material), the inserted HBV DNA in the vector was likely the 
factor that elicited a response. However, it remained unclear 
whether HBV DNA itself or the transcribed HBV RNAs medi-
ated the observed chemokine upregulation. To address this 
question, we inserted a luciferase sequence downstream of 
the CCL3 promoter region and stably expressed the construct 
in SK-Hep-1 cells. Then, total RNAs and cytosolic DNAs were 
isolated from HepG 2.2.15 cells, an HBV replication-competent 
cell line (42), and used for transfection as an HBV nucleic acid 
stimulator. Although the relationship between HBV RNAs and 
RIG-I has been identified (17), our data comparing the relative 
luciferase activity indicated that HBV DNA, rather than RNA, 
functioned more efficiently in the chemokine upregulation 
response (Figure 4A).
We next labeled HBV DNAs with 5′-biotin, transfected them 
into SK-Hep-1 cells, and then pulled down the DNA-binding 
proteins 6  h later. Through subsequent mass spectrometry 
analysis (Table S2 in Supplementary Material), we found that 
the most abundant HBV DNA-binding proteins were the 
Ku70/80 complex. The Western blot results also confirmed 
this observation (Figure  4B). Classically responsible for DNA 
repair reactions, the Ku70/80 complex is mainly localized into 
the nucleus. However, most of the HBV DNAs were cytosolic 
6 h after transfection. To directly examine the localization of the 
sensing reaction in the cells, we labeled the Ku70/80 complex by 
immunofluorescence. The confocal images revealed that without 
transfection stimulation, almost all of the complex molecules 
remained in the nucleus, whereas a substantial amount was trans-
ferred to the cytoplasm and colocalized with HBV DNAs 6 h after 
transfection (Figure 4C). Moreover, in HepG 2.2.15 cells, we also 
observed colocalization of Ku80 and HBcAg in the cytoplasm 
(Figure 4D). With total internal reflection fluorescence (TIRF) 
microscopy, colocalization of the HBcAg and Ku70 proteins was 
also visualized near the cell membrane (Figure  4E). Because 
HBV genomic DNA is reverse transcribed within the assembling 
core particle during replication (16), this colocalization suggests 
that HBV DNA could be recognized by the Ku70/80 complex in 
the cytoplasm.
Next, we investigated whether HBV DNA sensing by the 
Ku70/80 complex resulted in chemokine upregulation signals. 
We used RNA interference (RNAi) targeting Ku70 in SK-Hep-1 
cells (Figure 5A) and re-transfected the cells with HBV plasmid. 
Both the mRNA synthesis and protein secretion of CCL3 and 
CCL5 were reduced as a consequence of Ku70 knockdown 
(Figures 5B,C). These data show that HBV DNA sensing by the 
Ku70/80 complex leads directly to CCL3 and CCL5 upregulation.
Ku70/80 Drives Dna-PKcs and ParP1 
to Promote ccl3 and ccl5 expression
As mentioned earlier, the Ku70/80 complex is known for its 
DNA repair activities, which also require DNA-PKcs (28). 
Recently, a DNA-sensing function was reported for Ku70/80, in 
FigUre 5 | Knockdown of Ku70 expression impacts chemokine 
upregulation. (a) SK-Hep-1 cells were treated with Ku70 RNAi. Six hours 
later, the cells were harvested, and Western blotting was performed to 
measure Ku70 expression. (B,c) SK-Hep-1 cells were treated with RNAi 
against Ku70 24 h before pAAV-HBV1.2 plasmid transfection. Forty-eight 
hours later, the secreted CCL3 and CCL5 protein levels in the cell culture 
supernatant were determined by ELISA (B), and RT-PCR and real-time qPCR 
were performed to determine the mRNA expression (c) (n = 3).
FigUre 4 | The cytoplasm-translocated Ku70/80 complex recognizes transfected hBV Dna. (a) Total RNA and cytoplasmic DNA were isolated from HepG 
2.2.15 cells. RNA or DNA (1 μg/ml) was transfected into pCCL3p-luc-eGFP-expressing SK-Hep-1 cells. Forty-eight hours later, 150 μg/ml of firefly luciferin was 
added to the supernatant, and bioluminescence was determined immediately (n = 4). (B) Biotin-labeled HBV DNA was transfected into SK-Hep-1 cells. Six hours 
later, the cells were lysed, and the DNA-binding proteins were immunoprecipitated with a μMACS kit. Only beads were used as a control. Three rounds of column 
wash fluid (lysis buffer, marked Wash1–Wash3) were collected together with the high-salt eluent (1 M NaCl in lysis buffer, marked Elute) and the beads on the 
column (Marked Beads + DNA). Then, SDS-PAGE was carried out for Western blotting. (c) The pAAV-HBV1.2 plasmid was transfected into SK-Hep-1 cells. The 
cells were then fixed with PFA, and immunofluorescence staining was performed. An equal amount of medium or isotype IgG was applied as a control. Scale bars: 
10 μm. (D,e) HepG 2.2.15 cells were fixed, and immunofluorescence was assessed. Then, the slides were imaged under confocal (D) or wide-field and TIRF modes 
(e). Scale bars: 10 μm.
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which DNA-PKcs is involved, independently of its kinase activ-
ity (32). In our research, DNA-PKcs also co-precipitated with 
Ku70 after HBV DNA transfection (Table S3 in Supplementary 
Material). DNA-PKcs participated in CCL3 and CCL5 regula-
tion in a kinase activity-independent manner because inhibition 
of its kinase activity by Nu7026 had no effect on subsequent 
CCL3 and CCL5 upregulation (Figure 6A), while knockdown 
of DNA-PKcs inhibited this response (Figure  6B). Another 
DNA repair-related molecule, PARP1, was also a Ku70-co-
precipitated protein (Table S3 in Supplementary Material; 
Figure  6C). Consistent with the Ku70/80 complex, PARP1 
demonstrated significant cytoplasmic translocation after HBV 
DNA transfection (Figure 6D). Moreover, the colocalization of 
PARP1 and Ku70 was observed by super-resolution microscopy 
(Figure  6E). When we knocked down PARP1 in SK-Hep-1 
cells, the upregulation of CCL3 and CCL5 in response to HBV 
DNA transfection was affected significantly (Figure 6F). Thus, 
we believe that the Ku70/80 complex elicits both DNA-PKcs 
and PARP1 to activate the intracellular signaling cascade that 
upregulates the chemokines CCL3 and CCL5.
FigUre 6 | Ku70/80 elicits Dna-PKcs and ParP-1 to promote ccl3 and ccl5 expression. (a) SK-Hep-1 cells were pre-treated with Nu7026 (10 μM, 
DMSO as a control) 24 h before transfection with pAAV-HBV1.2 plasmid. Forty-eight hours post-transfection, the cells were harvested using RT-PCR and 
real-time qPCR assay (n = 3). (B) SK-Hep-1 cells were treated with RNAi against DNA-PKcs 24 h before pAAV-HBV1.2 plasmid transfection. Forty-eight hours 
post-transfection, the cells were harvested using RT-PCR and real-time qPCR assays (n = 3). (c) SK-Hep-1 cells were transfected with pAAV-HBV1.2 plasmid 
(medium as control). Six hours later, Ku70 was immunoprecipitated with antibody, with IgG1 as a negative control. The samples were analyzed by Western 
blotting. (D) pAAV-HBV1.2 plasmid was transfected into SK-Hep-1 cells. The cells were harvested 0–24 h post-transfection, and the cytosolic proteins were 
extracted using Western blot. (e) SK-Hep-1 cells were transfected with pAAV-HBV1.2 plasmid. Six hours later, the cells were fixed and immunofluorescently 
labeled. Subsequently, the cells were imaged under wide-field and GSD super-resolution modes. Scale bars: 10 μm. (F) SK-Hep-1 cells were treated with 
Ku70 RNAi 24 h before transfection of pAAV-HBV1.2 plasmid. Subsequently, RT-PCR and real-time qPCR were performed to determine the mRNA expression 
changes (n = 3).
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Because there are different DNA-sensing pathways in the 
cytoplasm, we investigated whether Ku70/80 sensing interacts 
with multiple DNA-sensing pathways. In addition to inflam-
masome-associated DNA-sensing pathways, which usually 
result in IL-1β and/or IL-18 production, the RNA polymerase 
III/RIG-I and cGAS-STING pathways are crucial methods of 
cytosolic DNA sensing (13). For this reason, we investigated 
whether members of these two pathways were recruited to 
the Ku70/80–DNA-sensing complex by immunofluorescence. 
However, confocal images showed neither RNA polymerase III 
nor cGAS colocalized with cytosolic Ku70 proteins (Figure S4A 
in Supplementary Material), which ruled out the possibility of 
their direct participation in the HBV DNA response. Because 
STING functions as a DNA-sensing adapter capable of activating 
both the IRF3 and NF-κB pathways, on which many cytosolic 
nucleic acid-sensing pathways rely, we examined the behavior 
of the STING protein post-transfection. The results suggested 
that STING did not assemble to the extent of activation and 
that IRF3 protein nuclear transfer did not occur (Figure S4B in 
Supplementary Material). Moreover, native PAGE and Western 
blotting showed that IRF3 proteins remained as inactive mono-
mers (Figure S4C in Supplementary Material). Furthermore, we 
found that inhibition of the NF-κB pathway did not affect the 
chemokine upregulation signal (Figure S4D in Supplementary 
Material). These results indicate no direct roles for typical DNA-
sensing pathways in Ku70/80 DNA sensing.
irF1 acts as the Key Transcriptional 
Factor That elicits ccl3 and ccl5 
expression
Immunofluorescence data from a previous publication clearly 
revealed the translocation of IRF3 to the nucleus after stimulation 
with DNA (32). However, in our model, IRF3 did not seem to be 
FigUre 7 | irF1 acts as the key transcription factor in this chemokine upregulation pathway. (a,B) SK-Hep-1 cells were transfected with pAAV-HBV1.2 
plasmid (medium as control). Six hours later, the cells were fixed and labeled using immunofluorescence. Subsequently, the cells were imaged using confocal (a) or 
GSD systems (B) Scale bars: 10 μm. (c) SK-Hep-1 cells were transfected with pAAV-HBV1.2 plasmid (medium as control). Six hours later, IRF1 was 
immunoprecipitated from the cell lysate. Western blotting was performed to analyze the Co-IP samples. (D) SK-Hep-1 cells were harvested at 3–24 h after 
pAAV-HBV1.2 plasmid transfection. IRF1 expression in the cytosol and nuclear was determined by Western blotting. (e,F) IRF1 (e) or IRF7 (F) expression was 
knocked down by RNAi in SK-Hep-1 cells 24 h before the transfection of pAAV-HBV1.2 plasmid. RT-PCR and real-time qPCR were subsequently used to determine 
the mRNA expression changes (n = 3).
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crucial, as it demonstrated no significant nuclear translocation 
after HBV plasmid transfection (Figures S4B,C in Supplementary 
Material). In another study, IRF1 and IRF7 were identified as the 
key transcription factors for activating type III interferon expres-
sion (31). Thus, we examined whether these transcription factors 
played a role in the Ku70/80-mediated chemokine upregulation 
response. We observed that IRF1 was assembled to DNA sites in 
the cytoplasm, and nuclear translocation occurred 6 h after trans-
fection, while IRF7 remained cytosolic (Figure 7A). Moreover, 
in GSD super-resolution images, cytosolic colocalization of 
Ku70 and IRF1 was observed upon HBV plasmid stimulation 
(Figure 7B), which implied a direct interaction. To confirm this 
result, we immunoprecipitated IRF1 and found increased binding 
of IRF1 to Ku70/PARP1 (Figure 7C). Meanwhile, the IRF1 protein 
abundance decreased significantly in the cytoplasm, compared to 
a moderate increase observed in the nuclear (Figure 7D). This 
response clearly indicated the activation and nuclear transfer of 
IRF1. Next, we knocked down IRF1 in SK-Hep-1 cells and then 
stimulated the cells with HBV DNA. As expected, CCL3 and 
CCL5 mRNA expression decreased dramatically (Figure 7E). In 
contrast, knockdown of IRF7 decreased only CCL3 expression 
(Figure 7F). From the above results, we can conclude that IRF1 
plays a crucial role as a key transcription factor in the Ku70/80 
sensing-mediated chemokine upregulation pathway.
DiscUssiOn
Previous publications suggest an essential role for chemokines 
in lymphocyte recruitment during hepatitis progression (3, 43). 
Chemokine secretion is commonly regarded as the consequence 
of interferon-mediated stimulation. However, HBV infection 
inhibits type I IFN production by host cells through HBV pro-
tein X (44). Here, we report a means of direct regulation of the 
chemokines CCL3 and CCL5 that are mediated by Ku70/80 sens-
ing of HBV DNA, and this mechanism is the missing link between 
HBV infection and lymphocyte recruitment. It has been reported 
that CCL5 expression is reduced in the serum of chronically 
HBV-infected patients (45). The cohort in that previous study had 
a normal serum ALT level, indicating mild liver inflammation. 
However, in our study, all patients had high serum ALT levels, 
suggesting severe hepatitis. Thus, both results suggest that CCL5 
is hepatitis associated. Moreover, our data show that the expres-
sion of CCL3 and CCL5 would be upregulated concomitantly in 
both acute phase and chronic phase patients with high ALT levels. 
When liver inflammation was relieved using antiviral treatment, 
the levels of chemokines were downregulated in both responders 
and non-responders (data not shown). These results suggested 
that these chemokines are closely related to liver inflammation 
and not to the other symptoms of hepatitis B. CCR5, as the main 
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receptor for CCL3 and CCL5, is expressed on various immune 
cells, including NK, NKT, CD4+ T, and CD8+ T cells, and its 
expression on the cell surface varies in response to HBV infection 
(27). Thus, the crosstalk between CCR5 and its ligands seems 
critical for the progression of hepatitis B.
Our experiments used an HBV DNA transfection model in 
SK-Hep-1 cells, an endothelium-derived liver cancer cell line 
(46), because these cells exhibit a similar chemokine upregula-
tion response to that of primary HSECs (Figure  3). Although 
HBV is the prototype of the hepadnavirus family, whose primary 
host is the hepatocyte, HSECs are also capable of HBV particle 
uptake (47), which means that it is possible that HBV DNA sens-
ing occurs in these cells. In addition to producing chemokines 
themselves, HSECs also possess chemokine transfer functions 
(48). As the major route by which circulating immune cells enter 
the liver (43, 49), HSEC-mediated increases in chemokine levels 
are an indication of liver inflammation and mediate the efficient 
recruitment of lymphocytes.
The amount of HBV DNA delivered to the cells was a crucial 
experimental parameter for the DNA-binding experiments. 
Consequently, we used the same concentration of labeled HBV 
DNA as the plasmid in the HBV plasmid stimulation experi-
ments (1 μg/ml) when performing the transfection. Therefore, 
the binding activity would occur intracellularly, similar to the 
HBV plasmid stimulation experiments, which avoided many 
non-specific protein interactions. Notably, the quantity of DNA 
that we introduced into cells is much higher than that in HBV-
infected cells. Therefore, the amount of HBV DNA level used 
for mass spectrometry identification of DNA-binding protein 
might not match that of natural HBV infection. Nevertheless, 
this kind of DNA transfection model was proved to be valid 
in DNA sensor identification by previous researches such as 
the finding of IFI16 sensing HIV cDNA in CD4+ T cells (22). 
Moreover, we observed colocalized HBcAg and Ku80 in the 
cytoplasm of HepG2.2.15 cells (Figures  4D,E), which sug-
gested natural binding of Ku proteins to HBV DNA. Our data 
also showed dose-dependent HBV DNA-mediated chemokine 
upregulation. Thus, the first wave of CCL3 and CCL5 chemokine 
secretion in vivo may be subtle, but it could still be capable of 
recruiting immune cells. The recruited cells early in infection 
interact with the infection microenvironment, leading to more 
cytokine secretion and more immune cell recruitment. Indeed, 
CCL3 and CCL5 upregulation mediated by HBV DNA sens-
ing by the Ku70/80 complex may initiate this type of cascade 
reaction.
As Ku70 and Ku80 are DNA repair-associated proteins, the 
Ku70/80 complex is predominantly localized to the nucleus, 
whereas DNA sensing primarily occurs in the cytosol. How 
this translocation is precisely achieved remains unclear. One 
hypothesis focuses on the dynamic equilibrium between nuclear 
and cytosolic Ku proteins. Cytosolic Ku proteins may bind to and 
assemble on exogenous DNAs upon viral infection, which would 
disrupt the equilibrium and drive Ku proteins from the nucleus. 
Our Ku70 Co-IP MS data (Table S3 in Supplementary Material) 
also suggest the binding of myosin and plectin, indicating an 
unknown mechanism of Ku protein transfer. Considering the 
similar DNA-binding role and similar subsequent molecules 
that they recruit within both DNA repair and cytosolic DNA-
sensing reactions, Ku proteins seem to recognize DNA with 
no bias. Nevertheless, the location of the recognition should 
indicate the type of reaction. Molecules used for DNA repair are 
abundant in the nucleus; thus, Ku proteins enter into DNA repair 
pathways without hindrance. However, in the cytosol, which is 
usually a DNA-free environment, molecules needed for DNA 
repair are rarely accessible. Instead, DNA-sensing pathways 
are much easier to deploy. Through an as-yet-undetermined 
mechanism, this results in increased IFN-λ and/or chemokine 
expression.
The Ku70/80 complex has been shown to be capable of 
sensing all types of DNA, with a preference for ssDNA and 
dsDNA with strand breaks (31), which is consistent with its 
DNA repair function. From minus-strand reverse transcription 
to relaxed circular DNA (rcDNA), HBV DNA in the cytoplasm 
of host cells always remains non-cyclic, which is consistent 
with the characteristics of Ku proteins. Notably, in the previous 
publication (22), the authors focused on the sensing function of 
IFI16. However, their data also demonstrated that the highest-
ranked proteins on the list of HIV DNA-binding proteins that 
were immunoprecipitated were Ku70/80 and PARP1. This may 
suggest that Ku70/80 elicits a common response upon sensing 
cytosolic DNA during infection by viruses that use a reverse 
transcription replication strategy.
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